Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 314
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04594252 | Copper Balance in Healthy Participants Administered ALXN1840 | ||
| NCT03759366 | A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) | ||
| NCT05234567 | A Prospective Sub-Study of the Global Hypophosphatasia Registry | ||
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | ||
| NCT05288673 | A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants | ||
| NCT02531867 | Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan | ||
| NCT06079372 | Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa | ||
| NCT01180790 | Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants | ||
| NCT04610580 | Bioavailability Study of 2 Oral Formulations of ALXN1840 | ||
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | ||
| NCT05686564 | Early Access Program for ALXN1840 in Patients With Wilson Disease | ||
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | ||
| NCT02245867 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | ||
| NCT01755429 | To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients | ||
| NCT03053102 | Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT04170023 | Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy | ||
| NCT05876351 | Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China | ||
| NCT03551743 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4) | ||
| NCT01895127 | Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation | ||
| NCT00122317 | Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT00894075 | Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) | ||
| NCT01193348 | An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome | ||
| NCT03766347 | Pediatric NMOSD Observational Study | ||
| NCT01176266 | Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) | ||
| NCT05780645 | A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants | ||
| NCT03555539 | Study of Danicopan in Participants With Hepatic Impairment | ||
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) | ||
| NCT01410916 | Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) | ||
| NCT01765855 | An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects | ||
| NCT00984113 | Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment | ||
| NCT01205152 | Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) | ||
| NCT06578949 | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT04609670 | Study of Radiolabeled ALXN2050 in Healthy Adult Males | ||
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | ||
| NCT06744647 | Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation | ||
| NCT03468140 | Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation | ||
| NCT01583218 | Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) | ||
| NCT02245412 | A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease | ||
| NCT06830798 | Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation | ||
| NCT05886244 | Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China | ||
| NCT06374264 | Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder | ||
| NCT04202341 | Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | ||
| NCT04730804 | A Study of ALXN1830 in Healthy Adult Participants | ||
| NCT02946463 | ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT02220725 | A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban | ||
| NCT02090179 | Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging | ||
| NCT01358370 | A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype | ||
| NCT02145182 | Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study) | ||
| NCT04526197 | Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. | ||
| NCT04355494 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 |
